Phathom Pharmaceuticals (PHAT) Gross Profit (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Gross Profit data on file, last reported at $46.3 million in Q1 2026.

• On a quarterly basis, Gross Profit rose 86.75% year-over-year to $46.3 million in Q1 2026; TTM through Mar 2026 was $174.0 million, a 146.53% increase from a year earlier, with the FY2025 full-year figure at $152.5 million, up 222.58% from the prior year.
• Gross Profit for Q1 2026 stood at $46.3 million, down from $49.9 million in the prior quarter.
• Over the last five years, Gross Profit for PHAT reached as high as $49.9 million in Q4 2025 and fell as low as $515000.0 in Q4 2023.
• Historically, Gross Profit has averaged $24.7 million across 4 years, with a median of $25.3 million in 2024.
• Across the five-year window, Gross Profit soared 4919.22% in 2024 and soared 86.75% in 2026, its largest moves.
• Year by year, Gross Profit stood at $515000.0 in 2023, then surged by 4919.22% to $25.8 million in 2024, then soared by 93.18% to $49.9 million in 2025, then dropped by 7.27% to $46.3 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $46.3 million in Q1 2026, $49.9 million in Q4 2025, and $43.3 million in Q3 2025.